Genetic prognostic and predictive markers in colorectal cancer

Axel Walther*, Elaine Johnstone†, Charles Swanton*, Rachel Midgley†, Ian Tomlinson† and David Kerr||

Abstract | Despite many studies of the likely survival outcome of individual patients with colorectal cancer, our knowledge of this subject remains poor. Until recently, we had virtually no understanding of individual responses to therapy, but the discovery of the KRAS mutation as a marker of probable failure of epidermal growth factor receptor (EGFR)-targeted therapy is a first step in the tailoring of treatment to the individual. With the application of molecular analyses, as well as the ability to perform high-throughput screens, there has been an explosive increase in the number of markers thought to be associated with prognosis and treatment outcome in this disease. In this Review, we attempt to summarize the sometimes confusing findings, and critically assess those markers already in the public domain.

Great strides have recently been made towards improving the survival outcome of patients with early and advanced colorectal cancer (CRC), but it remains a major health burden with over one million cases worldwide and a disease-specific mortality of approximately 33% in the developed world.

Despite the overall improvements in CRC therapy, our understanding of why individual patients respond to therapy and others do not, and why some patients relapse, whereas others do not, remains poor. Consequently, there is a large, unknown subset of patients who receive treatment from which they do not benefit. In the metastatic setting, this failure to benefit from treatment is easy to judge by demonstrating tumour progression using clinical assessment and radiological imaging. In the adjuvant setting, many patients must be treated, with significant attendant toxicity, so that a few might benefit, as there are clearly patients who would not have relapsed even without adjuvant therapy. Understanding the reasons for treatment failure and developing an ability to predict those who would benefit the most (and least) remain important aims in the management of CRC.

Currently, the gold standard for prognostication remains clinicopathological staging. The recommended staging system is the TNM classification, although systems based on that proposed by Dukes (Dukes staging system) in 1932 (REF. 4) are also used. Histopathological examination of tumour material can help to define prognosis further, using lymphovascular invasion, resection margins and tumour grade. In addition, some clinical parameters independently influence outcome: obstruction and perforation at presentation, performance status and pre-operative carcinoembryonic antigen levels, which probably reflect tumour burden at surgery. Although clinicopathological staging separates patients into groups with distinct outcomes, importantly it offers little information about response to treatment in individual patients.

Several protein and genetic markers have been described in an attempt to refine prognostic information and predict the benefit derived from systemic treatment. This could help to avoid the toxicities associated with systemic therapy in those patients who will not benefit from this treatment. None of these markers is in routine clinical use, but progress has been made in other tumour types towards such goals. In breast cancer, for example, hormone receptor status is associated with prognosis. There is also a clearer understanding of which patients benefit from trastuzumab therapy, and a gene expression signature conveying worse prognosis has been approved by the US Food and Drug Administration to support clinical decision making. Although the CRC community has lagged behind other cancers somewhat, there is now a growing knowledge base of analogous determinants and an increasing realization that well-designed trials are required to plot an approval pathway for the regulatory authorities.

In this Review we examine the range of prognostic markers and predictive markers in CRC, assess the clinical usefulness of those already published and discuss future strategies for discovery, with a focus on DNA- and RNA-based markers.
AJCC staging system

- The most studied markers of colorectal cancer prognosis and response to therapy are somatic mutations in KRAS, adenomatous polyposis coli (APC) and TP53. With the exception of KRAS mutations and their association with clinical resistance to epidermal growth factor receptor (EGFR)-specific antibody therapy, there is no compelling evidence that these markers have a role in clinical decision making.

- Chromosomal instability is associated with a worse prognosis, and microsatellite instability with a better prognosis.

- Germline polymorphisms have been described in the metabolic pathways of chemotherapeutic agents used in colorectal cancer — for example, 5-fluorouracil (5-FU) and irinotecan — which correlate with the degree of toxicity.

- High-throughput expression and genotyping arrays are starting to generate novel markers and gene signatures that may be of use in the management of colorectal cancer. At present, these are not sufficiently validated to be clinically useful.

- Linking the collection of tissue and germline DNA to well-designed clinical trials will increase our understanding of the mechanisms of poor prognosis, and with it our capacity to identify novel biomarkers.

Hypothesis-driven markers

Currently, the most studied markers are somatic (acquired) markers for which some biological rationale exists for a potential effect on cancer outcome. These are changes associated with tumour progression in the adenoma–carcinoma sequence model proposed by Vogelstein et al. (Fig. 1) or the observed type of genomic instability (chromosomal or microsatellite). Germline (inherited) changes have mostly been studied in pharmacological pathways involved in the metabolism and mechanism of action of 5-fluorouracil (5-FU), the therapeutic mainstay for CRC. These studies are all hypothesis-driven, with often limited a priori evidence to suggest a link to prognosis.

KRAS. Many studies have evaluated KRAS mutations in exon 2 (codons 12 and 13), and to a lesser extent in exon 3 (codon 61), for their association with CRC outcome. KRAS mutations are an early event in the adenoma–carcinoma sequence, although they are demonstrable in only approximately one-third of CRCs, with a large majority located in codon 12 (ref. 13). Mutations in each of the three codons compromise the ability of GTPase-activating proteins to effect the inactivating hydrolysis of Ras-bound GTP to GDP. Other mutations are uncommon as they result in lower constitutive Ras signalling than mutations in codons 12, 13 and 61 and so are selected against in the tumour (ref. 15).

Although the largest international effort to combine data from different groups, the RASCAL collaborative, found that KRAS mutations generally confer a worse prognosis, the subsequent analysis (which included a further 700 patients) found that only the glycine to valine substitution at codon 12 was associated with a poorer prognosis, and this was found only in American Joint Committee on Cancer (AJCC staging system) stage III patients (ref. 14). Other large studies have found no association (ref. 15), and there is currently no convincing evidence to suggest that KRAS mutations are independent prognostic factors in CRC.

More recently, however, KRAS mutation status has been established as a predictive marker for treatment with epidermal growth factor receptor (EGFR) inhibitors. This interaction was initially observed with small-molecule inhibitors of EGFR in non-small-cell lung cancer (ref. 21). However, several studies in CRC have now shown that, owing to the convergence of the EGFR and KRAS pathways (Fig. 2), patients with stage IV KRAS-mutant CRC being treated with the EGFR-specific antibodies cetuximab (ref. 22-26) and panitumumab (ref. 27) derive considerably less benefit than patients with wild-type KRAS tumours. Further, in 80% of KRAS wild-type patients treated with cetuximab, 11 patients with the BRAF V600E mutation (previously named V599E) (ref. 28) did not respond to the treatment (ref. 29). BRAF acts downstream from KRAS, and mutations in the two genes seem to be mutually exclusive (ref. 30); therefore, BRAF could be a locus for a second hit affecting the same pathway, and both genes are important determinants of resistance to EGFR-specific therapies.

KRAS is almost an ideal predictive biomarker: mutations are limited to a small part of the gene and are easily detected, the negative predictive value is high (99% of patients with mutated KRAS do not respond to EGFR inhibition) (ref. 31) and the effects of the mutations are based on a plausible biological rationale. Taking KRAS as an example further demonstrates how our evolving knowledge of cancer biology can refine treatment strategies and interventions, but also highlights the difficulties that the regulatory agencies will face when evaluating EGFR-specific or other targeted agents in response to retrospective clinical studies.

Adenomatous polyposis coli and β-catenin.

Adenomatous polyposis coli (APC) acts to promote the degradation of β-catenin and so limits the transcription of Wnt target genes involved in regulating the cell cycle. This pathway is integral to colorectal tumorigenesis, and more than 90% of patients have alterations that affect it (ref. 32). Given the frequency of changes, it is not surprising that neither APC nor β-catenin is a useful prognostic marker able to differentiate between patients. Although the specific type of APC mutation could hold prognostic information — for example, mutations that abolish β-catenin-binding sites of APC may be associated with poorer prognosis — addressing specific mutations in clinical practice could be technically difficult because of the large number of APC mutations already described. Testing for general overexpression of β-catenin does not seem to be useful, but determining the cellular location of overexpressed β-catenin may hold prognostic information (ref. 33), even if this overexpression is likely to be a surrogate marker for a genetic change elsewhere in the β-catenin degradation pathway. Changes in APC and β-catenin are therefore insufficiently validated in patients and currently have no role in clinical practice.

TP53. Loss of heterozygosity at chromosome 17p frequently occurs in CRC, and many studies have focused on the 17p region containing the TP53 tumour suppressor gene. TP53 has been investigated as both a prognostic factor and a predictor of response to therapy, with conflicting results. The methods used to assess the mutation of TP53 vary greatly between studies, as do study designs.
in terms of reported clinicopathological data and patient selection, making it difficult to draw firm conclusions about the prognostic value of p53 (REFS 35,36).

Loss of 18q. Deletion of the long arm of chromosome 18 is the most common cytogenetic abnormality in CRC and has been associated with poor prognosis37. However, as above, this is not a uniform finding38,39. Many studies have investigated the genes found in this region as prognostic markers, in particular deleted in colorectal carcinoma (DCC) without demonstrating a clear link to prognosis40. SMAD4, a known CRC predisposition gene that is also located on 18q, is a member of the transforming growth factor-β (TGFβ) signalling pathway, and decreased SMAD4 mRNA levels seem to be associated with a worse prognosis41 and poorer response to 5-FU42. However, not all studies have found a relationship between the loss of 18q and SMAD4 expression43; therefore, these studies have failed to definitively link any gene on 18q to prognosis. Furthermore, it seems likely that loss of 18q is a marker of chromosomal instability (CIN)44 and therefore not an independent prognostic marker, whereas the other common mutation in the TGFβ pathway in patients with CRC (mutation of TGFβ receptor 2) is almost exclusively linked to microsatellite instability (MSI)45.

Overall, somatic markers have proved to be of limited prognostic value in patients with CRC. This might reflect the fact that many of these changes are associated with molecular phenotype, and most (for example, mutations in Kras, APC and TP53, and loss of 18q) are much less common in patients with MSI46. Therefore, any somatic marker studied must be evaluated in the light of possible confounding by genomic instability.

Genomic and epigenomic instability

Two major types of genomic instability are recognized as alternative mechanisms of colorectal carcinogenesis. The more common, CIN (or aneuploidy), is present in approximately 65–70% of CRCs and is poorly defined as the presence of multiple structural or numerical chromosome changes in tumour cells. Around 15% of CRCs have a near-diploid chromosome set and MSI, defined as alternative mechanisms of colorectal carcinogenesis.
respectively. Strikingly, despite some studies not reporting significant associations, the direction of the effect is the same in virtually all contributory data.

Less clear is the prognostic relationship between CIN and MSI. The traditional view that CIN and MSI are mutually exclusive, and that all CRCs are either one or the other, is probably incorrect (Fig. 3). Although CIN and MSI may carry separate prognostic information, the only published study to date to assess the effect of both MSI and CIN in multivariate analysis did not find that the effect of MSI on survival was independent to that of CIN.90

CRCs also harbour epigenomic instability, either as global hypomethylation or as the CpG island methylator phenotype (CIMP), defined as methylation at three or more specific marker loci. CIMP has considerable overlap with MSI and seems to be associated with MSI in patients who do not have germline mutations in mismatch repair (MMR) genes, which are characteristic of hereditary non-polyposis colon cancer (also known as Lynch syndrome). In addition, BRAF V600E mutations are strongly associated with MSI and CIMP disease. Patients with this phenotype have been variably termed CIMP-high (CIMP-H) or CIMP 1 (Ref. 53) and have a better prognosis. A further group of patients with a CIMP- phenotype is associated with KRAS mutations and has been termed CIMP-low (CIMP-L) or CIMP 2 in response to the (not universally reported) lower levels of methylation. By contrast, MSI CRCs, which are CIMP- and harbour BRAF V600E mutations, are associated with a worse prognosis, and increasing levels of CIMP (negative to low to high) confer worsening prognosis in MSI CRC. Despite the finding in one study that MSI-associated prognostic information was not independent of CIMP status, the relative contributions of CIN, MSI and CIMP to survival outcome need to be further investigated to understand the effects and interactions of these variables.

Decreased methylation in the form of global genomic hypomethylation is also involved in colorectal carcinogenesis and is associated with CIMP, representing the opposite end of the methylation spectrum to CIMP- MSI CRC. CRC with genomic hypomethylation was associated with worse prognosis in one study, but this analysis did not include CIN status and, again, the interplay of the various types of genomic and epigenomic instability is not clear.

The consequences of each type of instability at the gene level remain poorly characterized, but it is now reasonable to use CIN and MSI status in clinical trials to stratify patients. CIMP and global hypomethylation should be evaluated further in retrospective series that are also determining CIN, MSI and BRAF status.

**MSI, CIN and drug sensitivity**

Since the initial publication of a detrimental effect of adjuvant 5-FU therapy in loco-regional MSI- CRC, further data have been published by the same group confirming their earlier findings. The clinical data are supported by *in vitro* evidence showing that a functioning MMR system is required for cytotoxicity in response to 5-FU incorporation into DNA, in addition to its effects mediated by inhibition of thymidylate synthetase (see below). By contrast, other retrospective data suggest that patients with MSI- CRC do benefit from adjuvant 5-FU administration. This is supported by the observation that in stage IV CRC, 5-FU treatment is effective in MSI- CRC. The conflicting data demonstrate the difficulty in examining uncommon subgroups. However, the evidence for a detrimental effect of 5-FU treatment is sufficiently strong for a clinical trial (ES202) to be undertaken to compare MSI- CRC without adjuvant chemotherapy to MSI- CRC with adjuvant chemotherapy. This clinical trial, which is now underway, aims to prospectively resolve these conflicting data.

In addition, there are data to suggest that MSI- CRCs are more sensitive to irinotecan-based regimens in some clinical series and cell line studies. The increased survival following irinotecan treatment in MSI- CRC was also observed in the adjuvant setting, in which irinotecan had failed to benefit unselected patients, making it an attractive proposition for prospective study in this setting.

CIN could also be a negative predictive marker for the response to taxanes, drugs that showed limited activity in CRC during their initial development. An intact spindle

---

Figure 2 | *The epidermal growth factor receptor signalling pathway.* On ligand binding, the epidermal growth factor receptor (EGFR) type 1 homodimerises, leading to the activation of the intracellular kinase domain. Through the small adaptor proteins Sos and Grb, the KRAS signalling cascade is activated, leading to increased proliferation. Part of the KRAS pathway is BRAF, which explains why non-constitutively activated KRAS and BRAF are necessary for EGFR blockade to work. The initial assumption that EGFR overexpression, as is common in colorectal cancer, is also required is challenged by a lack of correlation between EGFR expression and EGFR-specific antibody response and by the observation that patients with irinotecan-refractory, EGFR-negative colorectal cancer can still respond to irinotecan and cetuximab. JAK, Janus kinase; PLC, phospholipase C; STAT, signal transducer and activator of transcription.
assembly checkpoint is required for taxane sensitivity. In other words, only diploid cells segregate chromosomes normally and are sensitive to paclitaxel, a hypothesis that is currently being tested in a Phase II clinical trial in our institutions.

Pharmacogenetics of 5-FU and capecitabine
Inherited polymorphisms have the potential to greatly affect treatment: for conventional chemotherapy agents with a narrow therapeutic window, subtle genomic changes can modulate drug-specific pharmacokinetics or pharmacodynamics and substantially affect individual responses and toxicity after chemotherapy. Almost all chemotherapy regimes for CRC incorporate 5-FU or its oral prodrug, capecitabine, and the ability to tailor therapy to take into account variation in their metabolism has the potential to translate into beneficial effects for a large patient population (Fig. 4).

Thymidylate synthetase. Thymidylate synthetase (TS; also known as TYMS) is thought to be the dominant target for the active principle of 5-FU, fluorodeoxyuridine monophosphate (5-FdUMP). A meta-analysis of TS expression suggested that higher expression of TS is associated with a poorer overall survival rate. Two main genetic determinants of TS expression have been described: a variable number tandem repeat polymorphism in the TS promoter–enhancer region (TSE) and a 6 base pair (6 bp) insertion and deletion polymorphism in the 3′-untranslated region of TS. The tandem repeat sequence is 28 bp, and is usually present as either two or three repeats, although four and more repeats have been described. An increase in the number of repeats leads to increased efficiency of mRNA translation and expression. In addition, the G allele of a G–C single nucleotide polymorphism (SNP) when present in the second repeat of a three repeat sequence correlates with even higher mRNA expression through conservation of an upstream stimulatory factor binding site in which the SNP lies. The 6 bp deletion polymorphism in the 3′-untranslated region alters mRNA stability and is associated with low mRNA expression. The high expression variants have been associated with decreased survival in patients treated with 5-FU. These three markers may in combination predict which patients have an increased risk of recurrence in stage II and stage III colon cancer, reflecting a biologically aggressive phenotype that would also be resistant to 5-FU-based chemotherapy.

Dehydropyrimidine dehydrogenase. More than 80% of 5-FU is catabolised by dehydropyrimidine dehydrogenase (DPD) but levels of DPD activity can vary widely between individuals: 3–5% of the population is partially, and 0.2% completely, DPD deficient. There are more than 30 polymorphisms that cause DPD deficiency, leading to severe, sometimes life-threatening, toxicity after 5-FU treatment. The lower toxicity associated with modern infusional oral 5-FU-based regimens makes it impractical to screen the entire population for 30 polymorphisms a priori. Despite the obvious and logical effect on toxicity, its prognostic or predictive value is less clear: some studies report an association of mRNA expression levels with prognosis, whereas others do not, possibly reflecting differences in the clinicians’ responses to the encountered toxicity. Despite extensive investigation, the pharmacogenetic basis of varied DPD activity remains to be fully elucidated, although advances in high-throughput sequencing techniques may make the pre-treatment prediction of 5-FU toxicity achievable.

Methylenetetrahydrofolate reductase. Reduced methylenetetrahydrofolate reductase (MTHFR) activity creates variation in folate pools, indirectly increasing sensitivity to 5-FU. Two common polymorphisms in MTHFR lower enzyme activity: the C677T polymorphism leads to a change of alanine to valine at position 222 and A1298C, leading to severe, sometimes life-threatening, toxicity after 5-FU treatment. The lower toxicity associated with modern infusional oral 5-FU-based regimens makes it impractical to screen the entire population for 30 polymorphisms a priori. Despite the obvious and logical effect on toxicity, its prognostic or predictive value is less clear: some studies report an association of mRNA expression levels with prognosis, whereas others do not, possibly reflecting differences in the clinicians’ responses to the encountered toxicity. Despite extensive investigation, the pharmacogenetic basis of varied DPD activity remains to be fully elucidated, although advances in high-throughput sequencing techniques may make the pre-treatment prediction of 5-FU toxicity achievable.

Pharmacogenetics of oxaliplatin and irinotecan Oxaliplatin. There is some evidence to suggest that genetic polymorphisms in the genes that encode detoxifying enzymes and DNA repair proteins have an important role in determining the treatment response to the
The primary anti-tumour mechanism of platinum derivatives is the formation of DNA adducts, which interfere with DNA replication and repair the activity of DNA repair enzymes to avoid cell death. Several polymorphisms in different DNA repair enzymes have been shown to correlate with function; however, association studies with outcome seem to be regimen and cancer type specific. Of six commonly studied functional polymorphisms in four DNA repair genes (ERCC1, ERCC2, XRCC1 and XRCC3) only ERCC1 Asn118Asn and ERCC2 Lys751Gln were associated with overall survival in colorectal cancer in one report, but not in another report.

Irinotecan. The active metabolite of the topoisomerase I inhibitor irinotecan, SN-38, is conjugated and detoxified primarily by UDP-glucuronosyltransferase (UGT1A1). The number of TA repeats in the TATA element in UGT1A1 correlates with reduced enzyme expression and activity. Individuals who are homozygous for the 7-repeat allele, also known as the UGT1A1*28 allele, commonly suffer dose-limiting neutropenia through decreased degradation and clearance of SN-38. Initially, several groups reported this association, but their findings were heterogeneous in significance and effect size. A recent meta-analysis established that the incidence of toxicity in UGT1A1*28 patients was positively correlated with the dose used.

A commercial genetic test was approved by the US Food and Drug Administration in 2005 to make dosing recommendations based on UGT1A1 genotypic results and avoid life-threatening neutropenia, a first for any chemotherapy agent. The routine use of this test by oncologists has been limited in clinical practice because haematological toxicity has decreased with the lower irinotecan doses used in combination regimens with 5-FU. The prognostic impact of UGT1A1*28 has not been established.

Unbiased high-throughput screening

High-throughput arrays for evaluating mRNA expression levels or single nucleotide polymorphisms have opened new avenues of marker discovery by moving from hypothesis-driven, targeted research to unbiased screening of the whole genetic spectrum. RNA-based research is aimed at quantitative markers, whereas DNA-based techniques analyse discrete markers. The bulk of biomarker research has focused on somatic changes, but germline variation can equally have an impact on prognosis and response to therapy, although currently only the few pharmacogenetic markers mentioned in the previous section have been described. For prognostic purposes, gene expression analysis is classically carried out on tumour tissue, although comparative analyses with normal surrounding mucosa have been published, whereas genome-wide DNA screens have focused on the germline, particularly in the search for disease susceptibility loci.

Gene expression signatures. Gene expression analysis holds great promise for the understanding of the functional differences between tumour tissue and normal tissue, and with it the hope of developing meaningful signatures that stratify patients beyond pathological staging. In CRC, much effort has been expended to repeat the perceived success in breast cancer by analysing both tumour tissue and the surrounding mucosa. Similar analysis has also been applied to the study of microRNA (miRNA) arrays in tumour tissue.
The first published signature in CRC by Wang et al. identified a 23-gene prognostic signature based on 31 relapses in 74 stage II patients. This was subsequently subjected to validation both independently and by the same group. On the basis of 25 relapses in 50 stage II patients, the independent group found a positive predictive value of 67% (REF 102), only marginally better than chance, and therefore proposed a separate set of 30 genes. Wang et al. found that using only 7 genes of the original test set performed better in their validation set105, which this time was based on 123 patients and further validated in 104 patients. Similarly to other studies describing signatures based on differentially expressed genes (range 7 to 72), the overlap between the 30- and 7-gene signatures, even when in the same pathological stage, has been poor. One of the more convincing studies examined miRNA expression using 74 patients of all stages in the testing set and 110 patients in the validation set, and suggested a single miRNA (miR-21) as a prognostic marker. Again, this has not yet been validated further.

The reasons for the failure to find robust multi-gene signatures include that the studies were statistically underpowered, looking at sample sets as small as 20 patients but analysing the expression of tens of thousands of genes; that validation was not always carried out; and that correction for other prognostic variables was omitted from the main analysis, leading to overfitting of the prognostic model with poor reproducibility and a high false-discovery rate114. This problem is not unique to CRC, nor has the quality of studies improved with increased familiarity with the technology135-137.

Concerns have been raised for the first such signature, which was described in breast cancer, over the inclusion of the training set in the initial validation set118 and the use of patient numbers that were insufficient to derive a robust signature. Many different signatures could be derived from the same data, depending on the clustering parameters119, and a sample set of at least 3,000 patients may be necessary to identify a unique, robust signature20. Efforts are now underway to generate a gene expression signature from fixed paraffin-embedded tumour tissue using quantitative real-time PCR121. The initial signature was generated in a set of over 500 samples and will be validated in a large (n = 2,000) cohort of patients with colon cancer enrolled in the QUASAR trial122.

Meta-analysis is commonly carried out for other gene signatures, even when in the same pathological stage, and has been successful in identifying susceptibility loci for CRC127,128 prostate129 and breast cancer130, as well as non-malignant disease131,132. They have relied on the premise that many diseases have a heritable component and that traditional linkage analysis using a collection of affected families will only identify rare, high-penetrance susceptibility alleles. GWAS attempt to define common alleles that confer only a moderate risk for the disease in question.

It is likely that host factors (the genetic make-up of normal tissue) can have an influence on outcome, either as prognostic or predictive markers. Genetic variation associated with genes involved in cell adhesion and motility may make early metastasis more likely, and cell cycle checkpoint-associated variation may make the cell more tolerant to genomic abnormality and thus more resistant to chemotherapy. Pharmacogenomic variation is likely to have a role in both host response (toxicity) and tumour response to chemotherapy. This is discussed above, but GWAS have the potential to uncover new variants affecting the metabolism and efficacy of anticancer agents.

Until all genetic variation has been described and can be tested simultaneously, GWAS necessarily rely on the association of a tested marker with the true or causal variant affecting outcome, although there is no inherent reason why the tested marker could not be the true variant. This means that all identified markers need to be followed up irrespective of biological rationale, although if the marker identified is not in complete linkage disequilibrium with the true variant, replication would be more difficult. Once identified, however, routine clinical use would be easy, as the necessary DNA could easily be extracted from a standard blood sample and genotyping is robust.

It is possible to apply the same techniques to tumour DNA, although prognostic markers may arise from mutations in the malignant tissue and may not be captured by the SNPs analysed if these do not predispose to the mutation in the first place. Furthermore, the SNPs would not capture epigenetic events, which undoubtedly have a role in tumorigenesis and can also affect outcome. In malignant tissue, however, SNP typing platforms would give information about copy number changes (deletions, insertions and loss of homozygosity) that can affect gene expression (functional aneuploidy133).

To date, no GWAS looking at outcome, either in untreated or treated patients, have been published for any cancer. The main obstacle is that for the analysis of several hundred thousand SNPs, to retain a degree of statistical power, sample sets need to be large. Although it is easy to collect these sample sets for the analysis of risk, outcome requires follow-up for at least 3 years to assess progression-free survival with top-quality data in a clinical trial setting if at all possible.

GWAS of outcome in CRC are now underway, and one study has completed the initial screening phase of genotyping and testing the SNPs on the array for...
their association with outcome in 950 patients. The 40 SNPs most strongly associated have been validated in further, independent sample sets of similar sizes. Although there is likely to be a (substantial) proportion of SNPs that do not replicate, several of the SNPs taken forwards do look promising on the basis of the biological function of the genes in which they reside (kinases involved in cell cycle progression or tumour invasion) or the functional class of these genes, with 10 of the top 40 genes involved in cell adhesion and motility. However, it is important to test all significant SNPs from the screening phase, including those in regions without any genes in the vicinity, to ensure an unbiased approach and avoid moving into the hypothesis-driven search for markers described in the first section of this Review.

**Prospective clinical evaluation**

As stated previously, it is possible to test and validate CRC biomarkers using archived tissue and DNA, ideally linked to a statistically informative clinical trial with a control group of sufficient size to allow random separation of material into test and validation sets. This allows internal validation of the biomarker with outcome (progression-free being preferred to overall survival) using retrospective data. This may be sufficient to assess the statistical underpinning of the biomarker, but does not provide any formal test of its clinical utility. This is best achieved in prospective clinical trials designed to measure improvements in outcome and health economic parameters; however, different trial approaches are required for prognostic and predictive tests.

Assuming that the prognostic marker would separate the population of patients who are potential candidates for post-operative adjuvant chemotherapy into three statistically distinct groups, patients with a low risk of recurrence would receive no further therapy (they would be deemed cured by surgery alone), those with an intermediate risk would be randomized to conventional chemotherapy or control, and patients at the highest risk of relapse would be entered into a trial comparing conventional chemotherapy with the next generation combination.

If a predictive marker defines a subpopulation of patients who are particularly sensitive to a specific therapeutic intervention, the first investigative step would be to demonstrate the predictive value prospectively in small Phase II clinical studies: patients would be stratified according to marker status. Assuming a 30% response rate in those deemed to be sensitive and ≤10% in those who are not sensitive, 20–40 patients in the former and 15–20 patients in the latter group would give initial confidence in the power of the predictive biomarker to justify a randomized Phase III trial. A trial schema for the Phase III trial that could be used to demonstrate the clinical use of a predictive biomarker is outlined in Fig. 5.

**Conclusion**

The encouraging improvement in patient outcome over the past 20 years has been followed by a plethora of markers of prognosis and response to anticancer therapy, most of which fail to demonstrate clinical utility. Many more DNA- and RNA-based markers of prognosis than those mentioned in this Review have already been described, often only once and in a small series. Clearly there has to be considerably better validation before any can be thought of as being associated with prognosis or the response to therapy and therefore incorporated into clinical decision-making algorithms. With an increasing understanding of tumour biology, more hypothesis-driven markers will be evaluated, and unbiased screening will generate more hypotheses to be tested. Even for more widely studied markers, there is often little consensus about their true clinical value: the prognostic effect of the molecular phenotype, initially described many years ago, is only now entering prospective clinical trials.

Currently, the only marker with sufficient evidence to justify routine clinical assessment is KRAS mutational analysis and selection for EGFR-specific therapy. It is clear that a much greater degree of cooperation is required between basic and clinical scientists to bring sufficient rigour to bear on this field, designing trials with enough statistical power to provide results that will compel clinical engagement.
The classical model of colorectal carcinogenesis. Although increasing numbers of exceptions and additions are becoming apparent, this model describes the common mutations found in CRC.


The first description of the potential detrimental effect of adjuvant 5-FU chemotherapy in MSI-positive CRC.


97. This should be compulsory reading for anyone with an interest in gene expression signatures, as it underlines the pitfalls in analysing the expression data.


112. Well-conducted GWAS for risk of myocardial infarction, demonstrate the power of this strategy for novel marker discovery.
145. Kemp, Z. et al. CDC4 mutations occur in a subset of colorectal cancers but are not predicted to cause loss of function and are not associated with chromosomal instability. Cancer Res. 65, 11361–11366 (2005).